Inactive Instrument

News Nabriva Therapeutics PLC - ADR Nasdaq

Equities

US62957M1045

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-10-19	CI
Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index	23-07-31	CI
Sumitomo Pharma Co., Ltd. acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.	23-07-30	CI
Nabriva Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	23-07-24	PU
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer	23-07-10	MT
Nabriva Therapeutics plc Appoints H. Michael Hogan as Chief Executive Officer	23-07-07	CI
Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer	23-07-07	CI
Nabriva Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
NABRIVA THERAPEUTICS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-04-17	AQ
Nabriva Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Nabriva Therapeutics plc Auditor Raises 'Going Concern' Doubt	23-04-16	CI
Nabriva Therapeutics : Material Agreement - Form 8-K	23-02-06	PU
NABRIVA THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	23-02-06	AQ
NABRIVA THERAPEUTICS PLC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	23-01-20	AQ
Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer	23-01-20	CI
Nabriva Therapeutics : Termination of Material Agreement - Form 8-K	23-01-09	PU
NABRIVA THERAPEUTICS PLC : Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits (form 8-K)	23-01-09	AQ
Nabriva Therapeutics Provides Corporate Update	23-01-09	AQ
Health Care Up as Biogen Rises on Alzheimer's Drug Progress -- Health Care Roundup	23-01-06	DJ
Sector Update: Healthcare Stocks Rise Friday, Mostly Trail Other Sectors	23-01-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nabriva Therapeutics PLC - ADR Nasdaq

Equities

US62957M1045

Summary

Filters